Chenghao Chu

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele

Edith T. Zemanick, Jennifer L. Taylor‐Cousar, Jane C. Davies et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 288 citations · Full text

Pharmacy, Pediatrics, Pharmacology +15

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele

Jennifer L. Goralski, Jordana E. Hoppe, Marcus Mall et al. · American Journal of Respiratory and Critical Care Medicine · 2023 · 129 citations · Full text

Pharmacy, Pediatrics, Pharmacology +15

A randomized controlled trial testing a virtual perspective-taking intervention to reduce race and socioeconomic status disparities in pain care

Adam T. Hirsh, Megan Miller, Nicole A. Hollingshead et al. · Pain · 2019 · 70 citations · Full text

Medicine, Health Promotion, Health Equity +16

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Clinical Trial

Claire Wainwright, Susanna A. McColley, Paul McNally et al. · American Journal of Respiratory and Critical Care Medicine · 2023 · 65 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +14

Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials

Ahmet Uluer, Gordon MacGregor, Pilar Azevedo et al. · The Lancet Respiratory Medicine · 2023 · 64 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9